BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27754762)

  • 1. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
    Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
    Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
    Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
    Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer-Targeted Calcium Phosphosilicate Nanoparticles for Effective Imaging of Pancreatic and Prostate Cancer.
    Abraham T; McGovern CO; Linton SS; Wilczynski Z; Adair JH; Matters GL
    Int J Nanomedicine; 2021; 16():2297-2309. PubMed ID: 33776434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
    Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
    Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
    Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
    Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.
    Yoon S; Huang KW; Reebye V; Mintz P; Tien YW; Lai HS; Sætrom P; Reccia I; Swiderski P; Armstrong B; Jozwiak A; Spalding D; Jiao L; Habib N; Rossi JJ
    Mol Ther; 2016 Jun; 24(6):1106-1116. PubMed ID: 26983359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition.
    Wu X; Zhao Z; Bai H; Fu T; Yang C; Hu X; Liu Q; Champanhac C; Teng IT; Ye M; Tan W
    Theranostics; 2015; 5(9):985-94. PubMed ID: 26155314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.
    Smith JP; Harms JF; Matters GL; McGovern CO; Ruggiero FM; Liao J; Fino KK; Ortega EE; Gilius EL; Phillips JA
    Cancer Biol Ther; 2012 Feb; 13(3):164-74. PubMed ID: 22277584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging.
    Aloj L; Caracò C; Panico M; Zannetti A; Del Vecchio S; Tesauro D; De Luca S; Arra C; Pedone C; Morelli G; Salvatore M
    J Nucl Med; 2004 Mar; 45(3):485-94. PubMed ID: 15001692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
    Kryza T; Khan T; Puttick S; Li C; Sokolowski KA; Tse BW; Cuda T; Lyons N; Gough M; Yin J; Parkin A; Deryugina EI; Quigley JP; Law RHP; Whisstock JC; Riddell AD; Barbour AP; Wyld DK; Thomas PA; Rose S; Snell CE; Pajic M; He Y; Hooper JD
    Theranostics; 2020; 10(9):4116-4133. PubMed ID: 32226543
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma.
    Li H; Wang P; Deng Y; Zeng M; Tang Y; Zhu WH; Cheng Y
    Biomaterials; 2017 Sep; 139():30-38. PubMed ID: 28582716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
    Bahmani B; Uehara M; Ordikhani F; Li X; Jiang L; Banouni N; Ichimura T; Kasinath V; Eskandari SK; Annabi N; Bromberg JS; Shultz LD; Greiner DL; Abdi R
    EBioMedicine; 2018 Dec; 38():79-88. PubMed ID: 30497977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.
    Li Q; Maier SH; Li P; Peterhansl J; Belka C; Mayerle J; Mahajan UM
    Radiat Oncol; 2020 Aug; 15(1):189. PubMed ID: 32758252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma.
    Champanhac C; Teng IT; Cansiz S; Zhang L; Wu X; Zhoa Z; Fu T; Tan W
    Sci Rep; 2015 Nov; 5():16788. PubMed ID: 26603187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma.
    Kotopoulis S; Stigen E; Popa M; Safont MM; Healey A; Kvåle S; Sontum P; Gjertsen BT; Gilja OH; McCormack E
    J Control Release; 2017 Jan; 245():70-80. PubMed ID: 27871988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
    Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
    Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
    Wang H; Li X; Lai LA; Brentnall TA; Dawson DW; Kelly KA; Chen R; Pan S
    Biochimie; 2021 Feb; 181():25-33. PubMed ID: 33242496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma.
    Li J; Liu F; Gupta S; Li C
    Theranostics; 2016; 6(9):1393-402. PubMed ID: 27375787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.